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Do Captopril Renogram and Losartan Renogram
Influence the Choice of Drug (Angiotensin Converting
Enzyme Inhibitor/Angiotensin II Receptor Blocker)
to be Initiated in Renal Patients?
R. Ram, K.V. Dakshinamurty, Neela Prasad, Pushpalatha Sudhakar1
Background: The objectives of this study were to investigate the effects of angiotensin converting enzyme
(ACE) inhibitors and angiotensin (AT) II receptor blockers on glomerular filtration rate (GFR) as measured by
radionuclide renogram study, and to assess the value of changes in GFR modification with AT-II receptor
blocker/ACE inhibitor in determining the drug choice between ACE inhibitors and AT-II receptor blockers.
Methods: A total of 14 patients with type 2 diabetes or hypertension were subjected to baseline diethylene
triamine pentaacetic acid (DTPA) renogram followed by captopril and losartan renograms. The patients were
followed in a prospective randomized controlled crossover trial. Patients were treated with either enalapril or
losartan initially for 6 months, followed by the other drug in the later 6 months of the study period. Patients
with renal arterial disease, obstructive uropathy, urinary tract infection, acute renal failure or serum creatinine
more than 3 mg/dL were excluded from the study.
Results: Our data showed that irrespective of the initial choice of drug, either ACE inhibitor or AT-II receptor
blocker, there was an initial fall in GFR (noticed at 3 and 6 months) followed by an increase in GFR at the end
of 1 year. But neither the initial fall in GFR nor serum creatinine at the end of 6 months were different. This
shows that initial fall in GFR might not be associated with a rise in serum creatinine.
Conclusion: Patients may respond differently after intervention with captopril or losartan as evidenced by
radionuclide renogram study. The acute decline in GFR after captopril and losartan may be a pointer to the
utility of radionuclide DTPA renogram study in choosing which drug — ACE inhibitor or AT-II receptor blocker
— to use in patients requiring them. An acute increase in GFR may not always suggest lack of benefit with that
particular drug. This is especially true with AT-II receptor blockers, where the effects of AT2 receptors appear
to have an influential role. [Hong Kong J Nephrol 2006;8(2):61–7]
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INTRODUCTION
It is now 100 years since renin was first described by
Tigerstedt and Bergmann as a pressure system
originating in the kidney, and more than 60 years since
Goldblatt’s group demonstrated that hypertension could
be generated in dogs by constriction of one renal artery
[1], a procedure which in 1940 was shown to stimulate
renin (angiotensin) production by the ischemic kidney.
In 1970 came the first observations that angiotensin II
(AT-II) harms the heart and kidneys.
Saralasin, a peptidic antagonist of AT-II receptors,
was first to be used to treat hypertension and heart
failure via the blockade of the renin–angiotensin system
[2]. The next breakthrough came with captopril, the
first angiotensin converting enzyme (ACE) inhibitor.
Today, ACE inhibitors make an important contribution
to the control of hypertension and the treatment of
chronic heart failure. Since these drugs may reduce
proteinuria, they have also become an essential
component in the treatment of chronic renal diseases.
The renin–angiotensin system cascade starts with
the cleavage of angiotensinogen by renin to form
inactive decapeptide angiotensin I (AT-I). AT-I is then
converted by ACE into octapeptide AT-II. Alternative
enzymes to ACE, such as trypsin, cathepsin or heart
chymase, can also convert AT-I to AT-II. These routes
could explain why AT-II plasma concentrations are not
completely suppressed by chronic ACE inhibition. ACE
is also named kininase II because it participates in the
breakdown of bradykinin to inactive peptides. Bradykinin
is known to stimulate the release of vasodilatory
prostaglandins and nitric oxide from the endothelium [3].
Based on their different pharmacologic and
biochemical properties, two distinct subtypes of AT-II
receptors have been identified and designated as type
1 (AT1) and type 2 (AT2) receptors. While both AT1
and AT2 receptors belong to the seven transmembrane
G-protein coupled receptor family, the function of these
receptor subtypes is quite different.
Most of the well characterized actions of AT-II such
as vasoconstriction, cell proliferation and renal salt
retention are the result of stimulation of AT1 receptors.
Recent reports suggest that the activation of AT2
receptors exert antigrowth, antihypertrophic,
proapoptotic and hypotensive effects. AT2 receptor
activation has demonstrated vasodilatation of both
afferent and efferent glomerular arteries [4,5]. AT-II
promotes renal damage due to elevation of glomerular
capillary pressure since AT-II causes stronger constriction
in efferent arterioles than in afferent arterioles.
In an experimental model, glomerular filtration rate
(GFR) is reduced with ACE inhibitor administration,
while AT1 antagonist administration increased GFR,
although both induced comparable renal vasodilatation
and increases in glomerular plasma flow. Micropuncture
analysis of glomerular hemodynamics revealed that the
difference between the two classes of drugs with regard
to their effect on GFR is attributable to the greater ability
of ACE inhibitors to dilate efferent arterioles. The greater
efferent arteriolar dilatation with ACE inhibitor is
probably due to accumulation of bradykinin, which
causes marked vasodilatation only in efferent arterioles.
The other possible mechanisms are that AT1
antagonists reduce AT-II-mediated sympathetic
activation in the brain, AT-II accumulates due to AT1
receptor antagonism, and, peripherally, may reduce
adenosine generation through AT2 receptor activation.
Also, there is increased nitric oxide bioavailability
directly via AT2-receptor stimulation and indirectly via
bradykinin [6–8].
Interestingly, a crossover study comparing ACE
inhibitors and AT1 antagonists as monotherapy reported
that 18% (6/33) of patients responded to ACE inhibitors
but not to AT1 antagonists, and that 15% of these 33
patients responded to AT1 antagonists but not to ACE
inhibitors [9]. This finding highlights the differences
in the mechanisms of action between these two classes
of drugs.
Despite the immense amount of data on the efficacy
of ACE inhibitors and AT1 antagonists, which class of
drug to choose for an individual patient remains an
unanswered question, except that perhaps AT1
antagonists are to be preferred over ACE inhibitors due
to the poorer side effect profile of the latter. We
therefore aimed to identify whether or not radionuclide
renogram is an effective way to aid the clinician in
choosing the better of the two. In this study, the effect
of ACE inhibitor and AT-II receptor blocker on GFR as
measured by radionuclide renogram study was
investigated, and the value of enhanced GFR
modification with AT-II receptor blocker/ACE inhibitor
in determining the drug choice between ACE inhibitor
and AT-II receptor blocker was assessed.
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MATERIALS AND METHODS
Patients with diabetes mellitus or hypertension attending
the Department of Nephrology, Nizam’s Institute of
Medical Sciences, were considered for inclusion in this
study. Diabetes mellitus was defined according to the
criteria of the American Diabetes Association’s Clinical
Practice Guidelines 2000 [10], and hypertension was
defined according to the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure VI criteria [11]. Patients with renal
arterial disease, obstructive uropathy, urinary tract
infection, acute renal failure or serum creatinine more
than 3 mg/dL were excluded from the study. A total of
14 patients were included in this crossover prospective
randomized controlled trial according to the study design
shown in Figure 1. This study was approved by the
institute’s ethics committee.
After informed consent was obtained, patients were
instructed to stop all antihypertensive medication,
including ACE inhibitors and AT-II receptor blockers,
48 hours prior to the start of the 3-day protocol of
renography. On each of the 3 days, patients were
allowed to drink water but not to eat for at least 4 hours
before renography study. Renograms were taken under
the posterior view using a large field of view gamma
camera (Siemens Orbiter; Siemens AG, Munich,
Germany). On day 1, patients were investigated with
baseline diethylene triamine pentaacetic acid (DTPA)
renography using 222 MBq 99mTc-DTPA. On day 2,
renography was performed 1 hour after oral
administration of 50 mg captopril. On day 3, renography
was performed 1 hour after oral administration of 50
mg losartan. Renography was performed at the same
time on all 3 days of the study. Blood urea, serum
creatinine, serum electrolytes, serum calcium, uric acid,
phosphorus, total serum proteins, albumin, 24-hour
urine proteins, creatinine clearance and abdominal
ultrasound studies were also done.
Patients were randomized to either ACE inhibitor
(enalapril) or AT-II receptor blocker (losartan) for the
first 6 months and then crossed over to the other drug
(AT-II receptor blocker or ACE inhibitor) for the second
6 months. Every 3 months, patients were subjected to
DTPA renogram, blood urea, serum creatinine, serum
electrolytes, serum calcium, uric acid, phosphorus, total
serum proteins, albumin, 24-hour urine proteins, and
creatinine clearance studies. Individual kidneys’ GFRs
were estimated with Gates protocol and all renograms
were analyzed [12].
Results were expressed as mean ± standard
deviation. Student’s t test was used to determine
significance between variables, with p < 0.05 taken as
significant.
RESULTS
Of the 14 patients, 10 were men, nine were diabetics,
and five had hypertension; mean age was 49.54 ± 8.12
years. The mean baseline, post captopril and post
losartan GFR values (in mL/min/1.73 m2) were 64.05
± 26.07, 61.97 ± 23.70, and 64.15 ± 26.8, respectively.
Table 1 shows the comparison of the GFR of patients
with diabetes mellitus and those with hypertension, as
well as baseline GFR and changes with captopril and
losartan renograms.
Table 2 shows that in patients who received ACE
inhibitor, there was an initial fall in GFR (at 3 and 6
months), followed by an increase in GFR at the end of
1 year. Changes in GFR at the end of 1 year compared
to at 6 months, and at the end of 1 year compared to
initial GFR were significant (both p = 0.04). However,
the change in GFR at the end of 6 months compared to
initial GFR was not significant.
Table 3 shows that in patients who received AT-II
receptor blocker, there was also an initial fall in GFR
(at 3 and 6 months), followed by an increase in GFR
at the end of 1 year. Changes in GFR at the end of
1 year compared to at 6 months, and at the end of 1
year compared to initial GFR were both significant
(p = 0.032 and p = 0.04, respectively). However, the
change in GFR at the end of 6 months compared to
initial GFR was not.
Table 4 shows that there was an initial fall in GFR
(at 3 and 6 months), followed by an increase in GFR at
the end of 1 year irrespective of the initial drug of
choice. Changes in GFR at the end of 1 year compared
to at 6 months, and at the end of 1 year compared
to initial GFR were both significant (p = 0.032 and p =
0.036, respectively), but that at the end of 6 months
compared to initial GFR was not. Also, the difference
between the GFRs of the group initially on enalapril
(x) and of the group initially on losartan (y) was not
significant at the end of 1 year.Figure 1. Trial arrangement.
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Table 5 shows that serum creatinine (and all the
other biochemical parameters except for creatinine
clearance) at the end of 6 months and at 1 year were
not significantly different from the initial baseline
values.
Table 1. Comparison of glomerular filtration rate (GFR) between patients with diabetes mellitus and patients with hypertension*
Baseline GFR Post captopril GFR Post losartan GFR p
Diabetes mellitus 62.1 ± 22.7 60.5 ± 24.2 63.7 ± 24.3 NS
Hypertension 64.8 ± 27.4 62.5 ± 23.7 64.04 ± 27.9 NS
*Data are presented as mean ± standard deviation. NS = not significant.
Table 2. Follow-up glomerular filtration rate of patients (n = 8) randomized initially to enalapril and later to losartan after baseline
diethylene triamine pentaacetic acid (DTPA) renogram
Patient Baseline DTPA After 6 Difference After 1 year Difference
renogram (p) months (q) (q – p) (z) (z – q)
1 32.2 62.1 29.9 70.7 8.6
2 60.2 55.6 –4.6 72.8 17.2
3 66.4 54.9 –11.5 72.20 17.3
4 51.1 47.0 -4.1 65.9 18.9
5 68.5 30.8 –37.7 59.8 29.0
6 50.8 47.8 –3.0 43.98 –3.8
7 60.6 37.6 –23 70.6 33.0
8 55.2 40.2 –15 70.8 30.6
Mean ± SD 55.62 ± 11.46 47.0 ± 10.4 –8.6 ± 19.4 65.8 ± 9.8 18.8 ± 12.3
Table 3. Follow-up glomerular filtration rate of patients (n = 6) randomized initially to losartan and later to enalapril after baseline
diethylene triamine pentaacetic acid (DTPA) renogram
Patient Baseline DTPA After 6 Difference After 1 year Difference
renogram (p) months (q) (q – p) (z) (z – q)
1 42.2 72.1 29.9 82.7 10.6
2 62.2 59.6 –2.6 85.8 26.2
3 67.4 59.9 –7.5 87.5 27.6
4 51.3 47.8 –3.5 89.9 42.1
5 78.5 42.8 –35.7 77.9 35.1
6 50.1 38.8 –11.3 49.1 10.3
Mean ± SD 58.6 ± 13.2 47.3 ± 9.1 –5.1 ± 21.04 78.8 ± 15.1 25.3 ± 12.8
Table 4. Follow-up glomerular filtration rate (GFR) of all patients (n = 14)*
Baseline DTPA After 6 months Difference After 1 year Difference
renogram (p) (q) (q – p) (z) (z – q)
GFR of patients (n = 8) randomized 55.62 ± 11.46 47.0 ± 10.4 –8.6 ± 19.4 65.8 ± 9.8 (x) 18.8 ± 12.3
initially to enalapril and later to losartan
GFR of patients (n = 6) randomized 58.6 ± 13.2 47.3 ± 9.1 –5.1 ± 21.04 78.8 ± 15.1 (y) 25.3 ± 12.8
initially to losartan and later to enalapril
Follow-up GFR for all 14 patients 57.1 ± 12.3 47.1 ± 9.7 –6.8 ± 20.02 72.3 ± 12.4 22.0 ± 12.5
*Data are presented as mean ± standard deviation.
DISCUSSION
The aim of this study was to determine whether or not
radionuclide renogram study can be used to help select
an ACE inhibitor or AT-II receptor blocker selectively
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or in combination to derive maximum renoprotective
effect on a long-term basis, based on GFR modification
on intervention with captopril and losartan renograms,
which was tested prospectively in 14 patients in this
crossover study.
An analysis of 12 randomized clinical trials that
evaluated renal disease progression among patients with
preexisting renal insufficiency demonstrated that
patients manifested an acute fall in GFR, a rise in serum
creatinine, or both, after administration of ACE inhibitor
[13]. In patients with serum creatinine  124 μmol/L
( 1.4 mg/dL) randomized to an ACE inhibitor, a
55–75% risk reduction in renal disease progression was
demonstrated compared with subjects who had normal
renal function randomized to an ACE inhibitor. An
inverse correlation was observed between the degree
of renal function loss at baseline and the subsequent
rate of annual decline in renal function following
randomization to an antihypertensive regimen that
contained an ACE inhibitor. They could demonstrate
an association between acute increases in serum
creatinine of up to 30% that stabilize within the first 2
months of ACE inhibitor therapy and long-term
preservation of renal function. Therefore, the significant
difference between the falls in GFR after captopril and
losartan renograms indicates that renography does
indeed wield an influence on drug choice; the greater
the fall in the renogram, the better the drug.
The data of Apperloo et al [14] suggest that
reduction of intraglomerular hydrostatic pressure
may be relevant to the outcome of renoprotective
intervention in humans. In non-diabetic renal disease,
early renal hemodynamic response (but not the response
of systemic blood pressure) to antihypertensive therapy
predicts its long-term renoprotective efficacy. A slight
drop in GFR at the onset of treatment—which may
indicate a reduction in glomerular hydrostatic
pressure—predicts a favorable long-term course of renal
Table 5. Biochemical parameters of patients (n = 14) at baseline, 6 months and 1 year*
Parameter Baseline At 6 months At 1 year p
Hemoglobin (g/dL) 12.2 ± 1.1 12.0 ± 1.9 11.2 ± 1.8 NS
Blood urea (mg/dL) 45.6 ± 15.7 48.6 ± 14.7 49.8 ± 19.8 NS
Serum creatinine (mg/dL) 1.91 ± 1.93 1.93 ± 1.90 1.98 ± 1.90 NS
Serum sodium (mmol/L) 136 ± 4.8 134 ± 3.9 138 ± 3.0 NS
Serum potassium (mmol/L) 5.1 ± 4.8 5.0 ± 4.0 5.1 ± 4.6 NS
24-hour urine protein (mg/day) 607 ± 721.1 528 ± 527.1 430 ± 627.1 NS
Creatinine clearance (mL/min/1.73 m2) 41.5 ± 20.7 58.5 ± 25.7 68.0 ± 36.8 < 0.05
Total serum protein (g/dL) 6.3 ± 7.9 6.7 ± 5.7 6.3 ± 7.2 NS
Serum albumin (g/dL) 3.5 ± 3.6 3.4 ± 3.2 3.4 ± 3.4 NS
Serum cholesterol (mg/dL) 204.0 ± 54.7 219.0 ± 73.9 228.0 ± 81.3 NS
Serum triglycerides (mg/dL) 106.1 ± 76.0 124.1 ± 97.0 105 ± 85 NS
*Data are presented as mean ± standard deviation. NS = not significant.
function, suggesting that reduction in glomerular
pressure may play a role in long-term renoprotection
in humans (Figure 2).
Our data presented in Tables 2 and 3 show similar
results irrespective of the initial choice of drug (whether
ACE inhibitor or AT1 receptor blocker), i.e. there was
an initial fall in GFR (at 3 and 6 months) followed by
an increase in GFR at the end of 1 year. However,
neither the initial fall in GFR nor serum creatinine at
the end of 6 months were different. Thus, initial fall in
GFR might not be associated with a rise in serum
creatinine (Table 4).
Figure 2. Time course of glomerular filtration rate (GFR) before,
during, and after withdrawal of antihypertensive therapy in renal
patients. Black circles and solid lines represent patients who
initially showed a distinct fall in GFR (n = 20). White circles and
dashed lines represent patients in whom GFR did not fall at the
start of therapy (n = 20). After withdrawal of therapy, a rise in
GFR occurred in patients with an initial drop only, demonstrating
the functional nature of the initial drop in GFR. Interestingly,
withdrawal of treatment revealed that GFR is better preserved in
the patients who demonstrated an initial drop. Adapted with
permission from Reference 14.
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At the end of 1 year, our patients had received both
drugs, so it was difficult to determine the effect of each
drug. To determine the effects of the drugs on GFR
and to see significant changes in GFR may require the
drugs to be used for a longer duration.
Still, this does not answer the question of whether
or not renography can influence the choice between
ACE inhibitor and AT1 receptor blocker. Figures 3 and
4 show that patients with an initial decrease in GFR
after either captopril or losartan renogram had a
significant increase in GFR at the end of 1 year. Patients
with an initial increase in GFR after either captopril or
losartan renogram also had an increase in GFR at the
end of 1 year, but the different was not significant. The
reasons for the increase in GFR after captopril or
losartan renogram are not known, but an acute fall in
GFR after either captopril or losartan renogram appears
to be a sign of better preservation of GFR.
Ichikawa found a difference in the acute response
of GFR between ACE inhibitors and AT-II receptor
blockers [15]. While ACE inhibitors cause an initial
fall in GFR, which appears to be an essential
prerequisite for the subsequent attenuation of the
decline in GFR, AT-II receptor blockers are substantially
less potent in the initial lowering of GFR and have
subsequently limited attenuation in the decline of GFR.
In our study, patients who were on losartan had a better
final GFR than patients who were on enalapril. However
the difference was not significant. The reasons for this
are not clear but may be due to the effects of AT2
receptors.
In conclusion, our study has shown that the
acute decline in GFR after captopril and losartan may
be a pointer to the utility of radionuclide DTPA
renographic study in choosing which drug, either ACE
inhibitor or AT-II receptor blocker, to use in patients
requiring them. An acute increase in GFR may not
always suggest lack of benefit with that particular
drug. This is especially true with AT-II receptor
blockers, where the effects of AT2 receptors appear
to have an influential role.
REFERENCES
1. Goldblatt H, Lynch J, Hanzal RF. Studies on experimental
hypertension: I. The production of persistent elevation of systolic
blood pressure by means of renal ischemia. J Exp Med 1934;59:
347–79.
2. Brunner HR, Gavras H, Laragh JH. Angiotensin-II blockade in
man by sar1-ala8-angiotensin II for understanding and treatment
of high blood-pressure. Lancet 1973;2:1045–8.
3. Burnier M, Brunner HR. Angiotensin II receptor antagonists.
Lancet 2000;355:637–45.
4. Arima S, Ito S. Angiotensin II type 2 receptors in the kidney:
evidence for endothelial-cell-mediated renal vasodilatation.
Nephrol Dial Transplant 2000;15:448–51.
5. Endo Y, Arima S. Function of angiotensin II type 2 receptors in
the post glomerular efferent arteriole. Kidney Int 1997;52(Suppl
63):S205–7.
6. Agarwal R. Add-on angiotensin receptor blockade with maximized
ACE inhibition. Kidney Int 2001;59:2282–9.
7. Mombouli JV. ACE inhibition, endothelial function and coronary
artery lesions. Role of kinins and nitric oxide. Drugs 1997;54
(Suppl 50):12–22.
8. Sirgay HM, Carey RM. The subtype 2 (AT2) angiotensin receptor
mediates renal production of nitric oxide in conscious rats. J Clin
Invest 1997;100:264–9.
9. Stergiou GS, Skeva II, Baibas NM, Kalkana CB, Roussias LG,
Mountokalakis TD. Does the antihypertensive response to
angiotensin converting enzyme inhibition predict  the
antihypertensive response to angiotensin receptor antagonism?
Am J Hypertens 2001;14(7 Pt 1):688–93.
10. American Diabetes Association. Clinical Practice Guidelines 2000.
Diabetes Care 2000;23(Suppl):S1.
11. US Department of Health and Human Services, National Institutes
of Health, National Heart, Lung, and Blood Institute. The Sixth
Figure 4. Relationship of final glomerular filtration rate (GFR) to
the initial losartan renogram. The numbers in brackets are GFR values
in mL/min/1.73 m2. DTPA = diethylene triamine pentaacetic acid.
Figure 3. Relationship of final glomerular filtration rate (GFR)
to the initial captopril renogram. The numbers in brackets are
GFR values in mL/min/1.73 m2. DTPA = diethylene triamine
pentaacetic acid.
Hong Kong J Nephrol • October 2006 • Vol 8 • No 2 67
ACEi or ARB in renal patients
Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. National
Institutes of Health, National Heart, Lung, and Blood Institute,
National High Blood Pressure Education Program. NIH
Publication No. 98-4080, November 1997:p17.
12. Taylor AT Jr, Fletcher JW, Nally JV Jr, Blaufox MD, Dubovsky
EV, Fine EJ, et al. Procedure guideline for diagnosis of
renovascular hypertension. Society of Nuclear Medicine. J Nucl
Med 1998;39:1297–302.
13. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-
associated elevations in serum creatinine: is this a cause for
concern? Arch Intern Med 2000;160:685–93.
14. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term
antihypertensive treatment-induced fall in glomerular filtration
rate predicts long-term stability of renal function. Kidney Int
1997;51:793–7.
15. Ichikawa I. Will angiotensin II receptor antagonists be
renoprotective in humans? Kidney Int 1996;50:684–92.
